Laboratory of Neurological Disorders, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.
Department of Neurology, Centre for Global Health, Technical University of Munich, Munich, Germany.
J Neurol. 2022 May;269(5):2265-2274. doi: 10.1007/s00415-021-10848-4. Epub 2021 Oct 21.
Acute and post-acute neurological symptoms, signs and diagnoses have been documented in an increasing number of patients infected by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which causes Coronavirus Disease 2019 (COVID-19). In this review, we aimed to summarize the current literature addressing neurological events following SARS-CoV-2 infection, discuss limitations in the existing literature and suggest future directions that would strengthen our understanding of the neurological sequelae of COVID-19. The presence of neurological manifestations (symptoms, signs or diagnoses) both at the onset or during SARS-CoV-2 infection is associated with a more severe disease, as demonstrated by a longer hospital stay, higher in-hospital death rate or the continued presence of sequelae at discharge. Although biological mechanisms have been postulated for these findings, evidence-based data are still lacking to clearly define the incidence, range of characteristics and outcomes of these manifestations, particularly in non-hospitalized patients. In addition, data from low- and middle-income countries are scarce, leading to uncertainties in the measure of neurological findings of COVID-19, with reference to geography, ethnicity, socio-cultural settings, and health care arrangements. As a consequence, at present a specific phenotype that would specify a post-COVID (or long-COVID) neurological syndrome has not yet been identified.
急性和亚急性神经系统症状、体征和诊断在越来越多感染严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的患者中被记录下来,SARS-CoV-2 会导致 2019 年冠状病毒病(COVID-19)。在这篇综述中,我们旨在总结目前关于 SARS-CoV-2 感染后神经系统事件的文献,讨论现有文献的局限性,并提出未来的方向,以加强我们对 COVID-19 神经后遗症的理解。神经系统表现(症状、体征或诊断)在 SARS-CoV-2 感染开始时或感染期间存在与疾病更严重相关,表现在住院时间延长、住院死亡率更高或出院时仍存在后遗症。尽管已经提出了这些发现的生物学机制,但仍缺乏基于证据的数据来明确定义这些表现的发生率、特征范围和结果,特别是在非住院患者中。此外,来自中低收入国家的数据稀缺,导致 COVID-19 神经系统表现的衡量存在不确定性,涉及地理、种族、社会文化背景和医疗保健安排。因此,目前尚未确定特定的表型来指定 COVID-19 后的(或长 COVID)神经综合征。